The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 15.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130.
Turning Point Brands, Inc.
TPB · the NYSE · USD · Market cap $1.2B · 484 employees
Turning Point Brands, Inc., together with its subsidiaries, manufactures, markets, and distributes branded consumer products in the United States and Canada.
FAIL · Does not pass the screenPrice as of 17 Nov 2026Daily close, not a live quote
Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price49.51 USD at the 17 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 17 Nov 2026
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 3.19)
- Last reviewed17 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $81.00 to $95.12, base estimate $82.72 (screen dated 2026-11-17).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 3.19, read 2026-11-15
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Turning Point Brands, Inc. holds its Distribution at $49.51. The statistical read favours the buyers, held for 34 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the buyers, held for 34 days |
| Price at the screen | $49.51 |
| Valuation | 27.27 trailing · 28.16 forward price to earnings |
| Values screen | FAIL · score 30.0 |
| Beta | 1.09 |
Five Screens, Shown in Full
Does not pass. Prohibited business activity: Tobacco
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Prohibited business activity: Tobacco | Fail |
| Debt load | Excluded | Below 33% | Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | Excluded | Below 33% | Interest-bearing cash and securities are of assets, above the one-third limit. | Fail |
| Receivables | Excluded | Below 49% | Money owed to the company is of assets, above the 49% limit. | Fail |
| Revenue purity | Excluded | Below 5% | of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Turning Point Brands, does not clear the screen at the business-activity stage. It operates in tobacco, so the financial ratios are not the deciding factor here.
Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TPB's ethical verdict changes
Today TPB does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 17 Nov 2026: it trades at roughly a 40% discount to our $82.72 fair value, 22.60% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-17 screen. The gold marker is the market price at the same screen. A 40.1% discount to the base estimate.
Third-party analyst targets: 6 covering, consensus Strong Buy. The average target sits +143% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $82.72, with a range of $81.00 to $95.12, dated to the 2026-11-17 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsTobacco maker clears hurdles yet fails the screen
Picture a smoker in a small town reaching for familiar rolling papers or chewing tobacco at the counter. Those steady purchases keep Turning Point Brands growing revenue at 17 percent with a 12 percent profit margin and 23 percent return on equity. The numbers look solid on paper and the shares trade below the analyst median target, yet the business sits squarely in prohibited tobacco activity.
We pass for one clear reason. The ethical screen exists to keep us out of sectors that profit directly from harmful products, regardless of growth rates or margins. Forward earnings sit at 29 times and the moat remains unknown, but none of that matters once the screen flags the core activity.
Risk here is straightforward. Tobacco faces rising regulation, litigation and shifting consumer habits that can compress volumes quickly. The margin of safety versus our fair value offers little protection when the entire category carries permanent ethical exclusion. Analysis, not advice.
| Forward P/E | 28.2xpriced for continued growth |
| Trailing P/E | 27.3xa premium valuation |
| EPS, trailing | 2.32 |
| EPS, forward | 2.25 |
| Revenue growth | +22.6%strong top-line growth |
| Profit margin | 8.8%thin but positive margins |
| Return on equity | 17.6%a solid return on shareholder capital |
| FCF yield | -0.67% |
| Dividend yield | 0.35% |
| Debt to equity | 0.68moderate, manageable leverage |
| Current ratio | 5.67comfortably covers its short-term bills |
| Beta | 1.09moves a little more than the market |
| Short interest, float | 0.17% |
| 52-week range | 54.17 - 146.90 |
| Market cap | $1.2B |
| Employees | 484 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeTPB trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 16.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it none, with a mean price target of $130. Since the last review it its composite score eased.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Turning Point Brands (TPB) Opened Its First New York Flagship Pop Up Store Yahoo Finance · 8d ago
- Where Does Turning Point Brands (TPB) Valuation Sit On Mixed Q3 Results? Yahoo Finance · 8d ago
- Turning Point Brands (TPB) Stock Looks Cheap Even After A 200% Run Yahoo Finance · 8d ago
- Turning Point Brands, Inc. Q3 2026 Earnings Call Summary Yahoo Finance · 8d ago
- Turning Point Brands Inc (TPB) (Q3 2026) Earnings Call Highlights: Modern Oral Sales Double as ... Yahoo Finance · 8d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $92.71 | -13.6% | · | $864 | -13.6% |
| 2 months | $83.56 | -4.2% | · | $958 | -4.2% |
| 3 months | $88.88 | -9.9% | $0.08 | $902 | -9.8% |
| 6 months | $104.48 | -23.4% | $0.16 | $768 | -23.2% |
| 1 year | $73.55 | +8.9% | $0.31 | $1,093 | +9.3% |
| 2 years | $31.30 | +155.9% | $0.59 | $2,577 | +157.7% |
| 3 years | $22.05 | +263.2% | $0.86 | $3,671 | +267.1% |
| 5 years | $43.42 | +84.5% | $1.33 | $1,875 | +87.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever TPB does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.